

# AI & PARKINSON

Marjan Meinders,  
PhD

Radboudumc  
Nijmegen


# PARKINSON'S DISEASE

1886



- No neurologists
- No effective treatments
- Survival less than 10 years

Gowers WR (1886) A manual of diseases of the nervous system., J. & A. Churchill, London.




# LARGE DIFFERENCES BETWEEN INDIVIDUALS






# Monitoring response fluctuations



ON with  
dyskinesias

ON

OFF





# **personalized parkinson project**

Radboudumc

verily

Radboud Universiteit



umcg



Maastricht UMC+

Health~Holland



≡ provincie  
Gelderland



# OBJECTIVES

- **Primary objective:** to perform a set of hypothesis-driven analyses
- **Secondary objective:** evaluate the Verily Study Watch
- **Tertiary objective:** create an extensive longitudinal dataset and make this publicly available for researchers

# CHALLENGES FOR DATA SHARING

Protect the privacy and personal data of participants

Enable the use of data collected for legitimate research


If data are shared, receiving party obtains controllership over the data

What about subject's rights?

What about the obligations of the primary controller?



# PPP Program Principle: Privacy by design



# STUDY DESIGN

Single Center

520 people  
with  
Parkinson's

Recruitment of  
all 520 persons  
in 2 years

Longitudinal  
follow-up  
2 years

Total study  
duration  
5 years

## Inclusion criteria

- Parkinson's
- Since 0 – 5 years

## Exclusion criteria

- Severe co-morbidity
- Is not allowed to or does not want to undergo MRI

# DATA COLLECTION SCHEDULE




> 0,5 PetaByte of data

# VERILY STUDY WATCH



- Accelerometer
- Gyroscope
- Continuous heart rate
- Lead 1 ECG
- Ambient Pressure
- Ambient Temperature
- Ambient Humidity
- Ambient Light Sensor



**“Raw” sensor data**



**Reliable and  
clinically relevant  
measure for  
Parkinson**

# CHALLENGES FOR IA


- Large variation in daily life signals: small proportion Parkinson-specific
- Difficult to obtain labelled data in natural environments
- We need to be better than current labels
- Need for interpretability and outcomes that are meaningful for patients
- Often interested in causal effects



# APPLICATION FOR SELF TRACKING



*Sara Riggare*



# APPLICATION IN HEALTHCARE




- Optimizing medication dosing schedule
- Monitoring fall incidents
- Predict treatment effect


# DIGITAL PROGRESSION BIOMARKERS FOR CLINICAL TRIALS



MDS-UPDRS  
score



Sensor score



THANK YOU